

WO 00/15254

PCT/AU99/00770

1/12




Figure 1

WO 00/15254

PCT/AU99/00770

2/12




Figure 2

WO 00/15254

PCT/AU99/00770

3/12





Figure 3

WO 00/15254

PCT/AU99/00770

4/12



SUBSTITUTE SHEET (RULE 26) (R0/AU)


Figure 4

09/787111

WO 00/15254

PCT/AU99/00770

5/12




SUBSTITUTE SHEET (RULE 26) (RO/AU)

Figure 5

WO 00/15254

PCT/AU99/00770

6/12



SUBSTITUTE SHEET (RULE 26) (R0/AU)

Figure 6

09/787111

WO 00/15254

PCT/AU99/00770

7/12





Figure 7

09/787111

WO 00/15254

PCT/AU99/00770

8/12



SUBSTITUTE SHEET (RULE 26) (R0/AU)

Figure 8

WO 00/15254

PCT/AU99/00770

9/12





Figure 9

WO 00/15254

PCT/AU99/00770

10/12



SUBSTITUTE SHEET (RULE 26) (R0/AU)

Figure 10

WO 00/15254

PCT/AU99/00770

11/12

Anti-glycan mAbs prevent murine cerebral malaria




Figure 11

WO 00/15254

PCT/AU99/00770

12/12




Figure 12